LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it was expanding the company’s Scientific Advisory Board to help advance the company’s research and clinical studies. This Scientific Advisory Board will examine and support the scientific advancements that underlie the company’s novel inhaled cationic airway lining modulators (iCALM)™ platform, which has lead clinical candidates for COPD, asthma, and CF. Joining Pulmatrix’s Scientific Advisory Board are Richard Ulevitch, PhD, Tony Hickey, PhD, Peter Barnes, MD, Charles Wira, PhD, David Clapham, MD, PhD, Sanjay Sethi, MD, Mary Fitzgerald, PhD, and Richard Boucher, MD.
